--- title: "What Is Compounded Semaglutide?" description: "Learn what compounded semaglutide is, how it compares to Ozempic and Wegovy, its FDA status, safety profile, and why it costs significantly less." canonical: https://remevihealth.com/blog/what-is-compounded-semaglutide/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "REMEVi Medical Team" pubDate: 2026-04-08T00:00:00.000Z updatedDate: 2026-04-08T00:00:00.000Z tags: ["compounded semaglutide", "GLP-1", "weight loss", "telehealth", "Ozempic", "Wegovy"] alternateLanguage: https://remevihealth.com/es/blog/que-es-semaglutida-compuesta/ license: "© 2026 REMEVi LLC. AI assistants and search engines may quote and link to this page; please cite https://remevihealth.com/blog/what-is-compounded-semaglutide/ as the source." --- If you've been researching GLP-1 weight loss medications, you've likely heard the terms "Ozempic," "Wegovy," and "compounded semaglutide" used in the same breath — sometimes interchangeably. But there are important differences between them, and understanding those differences can help you make an informed decision about your health. This guide breaks down exactly what compounded semaglutide is, how it relates to brand-name medications, what the FDA says about it, and why cost is driving millions of Americans to explore this option. ## What Is Semaglutide? Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a class of medication that mimics a naturally occurring hormone in your gut. When you eat, your body releases GLP-1, which signals your pancreas to produce insulin, tells your liver to slow glucose release, and — crucially — sends satiety signals to your brain. Semaglutide is a synthetic version of that hormone with a longer half-life, meaning it stays active in your body for about a week from a single injection. Novo Nordisk, a Danish pharmaceutical company, developed semaglutide and markets it under two brand names: - **Ozempic** (approved for type 2 diabetes management, 0.5 mg – 2 mg doses) - **Wegovy** (approved specifically for chronic weight management, up to 2.4 mg doses) The active molecule is identical — semaglutide — but the two drugs are FDA-approved for different indications and at different dose ceilings. ## What Is Compounded Semaglutide? Compounded semaglutide is a version of semaglutide prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk. Compounding pharmacies are regulated by state pharmacy boards and operate under FDA oversight, and they have legally produced compounded drugs in the United States for decades. The key distinction is this: compounded semaglutide contains the same active pharmaceutical ingredient — semaglutide — but it is not the Ozempic or Wegovy product. It is typically prepared as an injectable solution and may be formulated with different inactive ingredients or as semaglutide base rather than semaglutide sodium. ### Why Does Compounded Semaglutide Exist? The primary reason compounded semaglutide became widely available is a prolonged national shortage of Ozempic and Wegovy. Starting in 2022, demand for semaglutide-based weight loss medications skyrocketed — fueled in part by social media coverage and increasing recognition of obesity as a chronic, treatable disease. Novo Nordisk's manufacturing capacity could not keep pace with demand. Under Section 503B of the Federal Food, Drug, and Cosmetic Act, when a brand-name drug is on the FDA's drug shortage list, licensed compounding pharmacies and outsourcing facilities may legally compound that drug. Ozempic and Wegovy remained on the shortage list through 2024, during which time compounding pharmacies ramped up production of compounded semaglutide significantly. ## How Compounded Semaglutide Differs from Ozempic and Wegovy Understanding the differences helps you evaluate your options clearly: ### Manufacturer and Formulation Ozempic and Wegovy are manufactured by Novo Nordisk in FDA-inspected facilities with standardized quality controls. Compounded semaglutide is prepared by compounding pharmacies, which vary in quality. Reputable compounding pharmacies — particularly those registered as 503B outsourcing facilities — are inspected by the FDA and maintain high standards. Choosing a pharmacy that holds 503B status is an important quality marker. ### Regulatory Approval Ozempic and Wegovy are FDA-approved drugs, meaning they have undergone rigorous clinical trials demonstrating safety and efficacy. Compounded drugs are not FDA-approved individually, but the active ingredient — semaglutide — is itself FDA-approved. The compounding process creates a new preparation, not a new molecule. ### Dosage Flexibility One clinical advantage of compounded semaglutide is that it can be dosed flexibly. Rather than following the manufacturer's fixed titration schedule, a prescribing physician can write a prescription that adjusts the dose to a patient's specific tolerance and response. This is particularly useful for patients who experience significant side effects at standard doses and benefit from a slower titration. ### Cost This is where the differences become financially significant. Brand-name Wegovy carries a list price of approximately **$1,349 per month** in the United States without insurance coverage. Ozempic's list price is similar. Insurance coverage for weight management medications remains limited — many plans cover Ozempic for diabetes but not for weight loss. Compounded semaglutide, when sourced through a telehealth provider with pharmacy relationships, typically costs **$150–$350 per month**, depending on dose and provider. That's a reduction of 75–90% compared to brand-name medications. ## The FDA's Current Position on Compounded Semaglutide The regulatory landscape for compounded semaglutide has evolved quickly, and staying current is important. In **February 2025**, the FDA determined that the shortage of tirzepatide (Mounjaro/Zepbound) had been resolved and moved to restrict compounding of that drug. The FDA announced that it was reviewing the shortage status of semaglutide products as well. In **March 2025**, the FDA declared the shortage of semaglutide resolved. Under Section 503B, this means that large outsourcing facilities are no longer permitted to compound semaglutide for general distribution. However, **503A compounding pharmacies** — those that compound for individual patient prescriptions from a licensed prescriber — may still legally prepare compounded semaglutide when there is a valid patient-specific prescription and a documented clinical rationale. This means that access to compounded semaglutide has narrowed somewhat from its 2023–2024 peak, but it remains available through certain telehealth providers and compounding pharmacies operating within the 503A framework. **At REMEVi, we work exclusively with licensed 503A compounding pharmacies and ensure that every prescription is written by a licensed medical professional following a thorough clinical intake.** We stay current on FDA guidance and update our clinical protocols accordingly. ## Safety Considerations Is compounded semaglutide safe? The honest answer involves nuance. The active ingredient — semaglutide — has an extensive clinical safety record. The SUSTAIN and STEP clinical trial programs (each involving thousands of participants over multiple years) demonstrated that semaglutide is effective for blood sugar control and weight management, with a well-characterized side effect profile. However, several safety concerns apply specifically to compounded versions: ### Purity and Potency Variability Not all compounding pharmacies maintain the same quality standards. In 2023 and 2024, the FDA issued warnings about compounded semaglutide products that were found to contain incorrect concentrations or unlabeled additives. The FDA also flagged some products that used semaglutide sodium or semaglutide acetate rather than the base form used in FDA-approved products — with uncertain clinical implications. **This is why pharmacy selection matters.** Working with a telehealth provider who has vetted their pharmacy partners — and specifically uses 503A-compliant pharmacies — significantly mitigates this risk. ### No Pen Device Ozempic and Wegovy are delivered via pre-filled injection pens that make dosing straightforward. Compounded semaglutide typically comes in multi-dose vials requiring patients to draw their own dose with a syringe. While this is a manageable process for most patients, proper patient education on injection technique is essential. ### Medical Supervision Is Non-Negotiable GLP-1 receptor agonists are prescription medications for good reason. They interact with other medications, are contraindicated in patients with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and require monitoring over time. Any use of compounded semaglutide should be under the ongoing supervision of a licensed medical professional. ## Who Is a Good Candidate? Compounded semaglutide may be appropriate for adults who: - Have a BMI ≥ 30, or BMI ≥ 27 with at least one weight-related health condition (type 2 diabetes, hypertension, sleep apnea, dyslipidemia) - Have tried lifestyle modifications without sufficient results - Cannot access or afford brand-name Ozempic or Wegovy - Do not have contraindications to GLP-1 receptor agonists - Are committed to ongoing medical follow-up Compounded semaglutide is **not appropriate** for patients with a personal or family history of MEN2 or medullary thyroid carcinoma, those who are pregnant or breastfeeding, or those with severe gastrointestinal disease. ## What Results Should You Expect? Clinical data from the STEP trial program offers a reliable benchmark. In STEP 1 — a 68-week randomized controlled trial of semaglutide 2.4 mg in adults with obesity — participants lost an average of **14.9% of their body weight**, compared to 2.4% in the placebo group. A meaningful proportion of participants (32%) lost more than 20% of their body weight. These results are from brand-name Wegovy. Compounded semaglutide, when using the same active molecule at the same dose, is expected to produce similar outcomes — though head-to-head trials comparing compounded and brand products have not been conducted. Real-world results vary. Weight loss on semaglutide depends on the dose achieved, adherence, dietary patterns, physical activity, and individual metabolic factors. Telehealth programs that pair medication with behavioral support consistently show better outcomes than medication alone. ## How REMEVi Approaches Compounded Semaglutide At REMEVi, our approach to GLP-1 medications is grounded in clinical rigor and accessibility. We believe that cost should not be the barrier that prevents someone from accessing a safe, effective treatment for a serious chronic disease. Our process: 1. **Clinical intake**: Complete health history, review of contraindications, baseline vitals 2. **Medical review**: A licensed REMEVi provider reviews your intake and determines whether you are a candidate 3. **Prescription**: If appropriate, a prescription is written specifying dose and titration schedule 4. **Pharmacy fulfillment**: We work with licensed 503A compounding pharmacies with established quality standards 5. **Ongoing monitoring**: Monthly check-ins, dose adjustments as needed, management of side effects We operate bilingually — all of our clinical intake, provider consultations, and patient education materials are available in both English and Spanish. We recognize that language access is a healthcare equity issue, not a convenience feature. ## Getting Started If you've been researching compounded semaglutide and want to know whether it's right for you, the best first step is a clinical intake with a qualified provider — not a social media post or a friend's experience. **Ready to see if you qualify?** [Start your free intake at REMEVi today.](/get-started/) --- *Medical Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. Compounded semaglutide is a prescription medication and should only be used under the supervision of a licensed healthcare provider. Individual results vary. The FDA has not evaluated compounded semaglutide for safety or efficacy as it would a brand-name drug. Consult your healthcare provider to determine whether this medication is appropriate for your specific health situation.*